Hemophilia | Marketed Drugs update.
'Advate targets broadest patient segment in hemophilia A'
By Natasha Spiller, Analyst
19 August 2013
I am an Analyst at Datamonitor Healthcare. After joining the company in 2012, I have produced analysis across a number o...
Read full bio
In-depth analysis of marketed drugs for hemophilia across the US, Japan, and five major EU markets (France, Germany, Italy, Spain and the UK).
Includes clinical data and provides an evaluation of clinical and commercial drug attributes to determine competitiveness in the marketplace.
Recombinant clotting factors have significantly changed the treatment landscape for patients with hemophilia by providing a therapy with a reduced risk of viral transmission, offering patients a safer therapeutic option than human plasma-derived therapies.
Developers have enhanced recombinant clotting factor therapies by improving their purity, safety, and ease of administration. However, the forthcoming launch of long-acting pipeline therapies will threaten the position of well-established brands.
This is a Cardiovascular analysis update from the Datamonitor Healthcare service, which provides regular and event-senstive research for key drugs and companies, treatment trends, patient populations and strategic issues.
- For more information on this research, please contact
- For current clients, please log-in to view the full analysis at: